“We have been invested in Anocca throughout its preclinical development and are pleased to see the company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies,” says Johan Andersson, Chairman of Mellby Gård.

This support is a very strong vote of confidence in the ability of Swedish and Nordic life sciences to build and compete globally.

Reagan Jarvis, CEO, Anocca

“This financing brings our cumulative raise to around SEK 2 billion, signaling that our Nordic investor base share our clear and consistent vision – to expand availability of targeted T-cell therapies to more cancers and unlock these transformative treatments for solid tumors. Over the past decade we have built novel technologies and extensive capabilities, including internal manufacturing, to execute on this vision,” says Reagan Jarvis, co-founder and CEO, Anocca to NLS.

“This support is a very strong vote of confidence in the ability of Swedish and Nordic life sciences to build and compete globally. We are proud to be a Swedish company, and in a country that is a magnet for global talent (130+ staff from 40 nationalities),” he says.

The first non-viral gene-edited TCR-T cell therapy in Europe with recruitment open

The capital will be used to support the execution of our clinical trials in VIDAR-1, describes Jarvis.

“The first trial in this program, targeting Pancreatic Ductal Adenocarcinoma (PDAC) with mutant KRAS, is currently open for recruitment at top university hospitals in Northern Europe. This will be the first non-viral gene-edited TCR-T cell therapy in clinical development in Europe,” he says to NLS.

Related article

Scaling the next generation of T-cell therapy

Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product. 

The continued progress and the future

“In additional to the trial, this financing will also support the continued progress of our pipeline. Our unique platform has been purposefully built to address a critical missing piece to scaling precision cell therapies across oncology indications – rapid and cost-effective discovery to provide more tumor-selective targets, more high-quality targeting receptors, with which to deploy more novel products to clinic,” says Reagan Jarvis.

“We are proud of having built the organization to this current stage and look forward to seeing our therapies bring benefit to patients with serious unmet medical need,” he adds.